Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are "concerned that the current regulations allow some patients to ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...